medigraphic.com
Instituto Nacional de Salud Pública

2021, Número 2

<< Anterior Siguiente >>

salud publica mex 2021; 63 (2)


La evidencia de la política en la regulación de los ácidos grasos trans en México

Oluwaseyidayo II, Adom ME, Gavkalova N

Idioma: Español
Referencias bibliográficas: 43
Paginas: 268-273
Archivo PDF: 354.95 Kb.


RESUMEN

Según la Organización Mundial de la Salud, las muertes causadas por enfermedades coronarias (EC) representaron una quinta parte del total de muertes en México en 2017. Investigaciones realizadas en el pasado han confirmado la asociación entre los ácidos grasos trans (AGT) en la dieta y las EC. Los AGT de la dieta se derivan principalmente de aceites hidrogenados industriales, productos lácteos y grasas cárnicas. Este trabajo tiene como base un documento de política pública acerca de las políticas internacionales para AGT en países de ingresos bajos a medianos, utilizando a México como estudio de caso. Sin embargo, esta reelaboración tiene como objetivo analizar críticamente el proceso de políticas de regulación de AGT en México, mediante la evaluación de la solidez de la evidencia propuesta y la identificación de las barreras que impiden el uso de la misma para la implementación de una política de regulación de AGT. Aunque abundan las evidencias para fundamentar políticas de regulación de los AGT, la falta de colaboración y comunicación efectivas entre los principales actores (investigadores, formuladores de políticas y consumidores) en México sigue siendo un gran obstáculo en su implementación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lee J, Davies P. Is Evidence-Based Government Possible? Jerry Lee Lecture, presented at the 4th annual Campbell Collaboration Colloquium. Washington DC, USA, 2004 [cited 2020 Jan 5]. Available from: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.545.364&rep= rep1&type=pdf

  2. Wolf A. Civil society: the critical history of an idea. By John Ehrenberg. Am Polit Sci Rev. 2000;94(3): 703-4. https://doi.org/10.2307/2585844

  3. Flyvbjerg B. Making Social Science Matter. Why social inquiry fails and how it can succeed again. Cambridge, United Kingdom: Cambridge University Press, 2001. https://doi.org/10.1017/CBO9780511810503

  4. Ruwaard D, Kramers PGN, van den Berg Jeths A, Achterberg PW. Public Health Status and Forecasts. The health status of the Dutch population over the period 1950-2010 431501016 [Internet]. Netherlands: Rijksinstituut voor Volksgezondheid en Milieu, 1993[cited 2020 Jan 5]. Available from: https://www.rivm.nl/bibliotheek/rapporten/431501016.html

  5. Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: A framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis. 1985;38(4):339-51.

  6. U.S. Congress, Office of Technology Assessment. Identifying Health Technologies That Work: Searching for Evidence. Washington, DC: U.S. Government Printing Office, 1994 [cited 2020 Jan 5]. Available from: https://www.princeton.edu/~ota/disk1/1994/9414/9414.PDF

  7. Mcginnis JM, Lee PR. Healthy People 2000 at Mid Decade. JAMA. 1995;273(14):1123-9.

  8. Perez-Ferrer C, Lock K, Rivera JA. Learning from international policies on trans fatty acids to reduce cardiovascular disease in low- and middle-income countries, using Mexico as a case study. Health Policy Plan. 2010;25(1):39-49. https://doi.org/10.1093/heapol/czp040

  9. Hajar R. Framingham contribution to cardiovascular disease. Hear Views. 2016;17(2):78.

  10. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89-92.

  11. Ríos AM. Most common causes of death in Mexico 2017 [Internet]. Statista: 2018 [cited 2020 Jan 5]. Available from: https://www.statista.com/ statistics/960030/mexico-causes-death/

  12. Agide FD, Garmaroudi G, Sadeghi R, Shakibazadeh E, Yaseri M, Koricha ZB, et al. Application of Kingdon and Hall Models to review environmental sanitation and health promotion policy in Ethiopia: a professional perspective as a review. Ethiop J Health Sci. 2019;29(2):277-86.

  13. Downs SM, Thow AM, Leeder SR. La eficacia de las estrategias para reducir las grasas trans en la dieta: Examen sistemático de los datos disponibles. Bull World Health Organ. 2013;91(4):237-312.

  14. Monge-Rojas R, Colón-Ramos U, Jacoby E, Mozaffarian D. Voluntary reduction of trans-fatty acids in Latin America and the Caribbean: current situation [Internet]. Rev Panam Salud Publica. 2011;29(2):126-9 [cited 2020 Jun 28]. Available from: https://iris.paho.org/handle/10665.2/9563

  15. Ramírez-Silva I, Villalpando S, Moreno-Saracho JE, Bernal-Medina D. Fatty acids intake in the Mexican population. Results of the National Nutrition Survey 2006. Nutr Metab [Internet]. 2011;8(33)[cited 2020 Jun 28]. Available from: https://nutritionandmetabolism.biomedcentral.com/ articles/10.1186/1743-7075-8-33

  16. Monge-Rojas R, Colón-Ramos U, Jacoby E, Alfaro T, Do Carmo MDGT, Villalpando S, et al. Progress towards elimination of trans-fatty acids in foods commonly consumed in four Latin American cities. Public Health Nutr. 2017;20(13):2440-9. https://doi.org/10.1017/S1368980017001227

  17. Downs SM, Bloem MZ, Zheng M, Catterall E, Thomas B, Veerman L, et al. The impact of policies to reduce trans fat consumption: a systematic review of the evidence. Curr Dev Nutr. 2017;1(12):cdn.117.000778. https://doi.org/10.3945/cdn.117.000778

  18. Rubinstein A, Elorriaga N, Garay OU, Poggio R, Caporale J, Matta MG, et al. Élimination des acides gras trans artificiels en Argentine: Effets estimés sur la charge des cardiopathies coronariennes et sur les coûts associés. Bull World Health Organ. 2015;93(9):614-22.

  19. NCD Alliance. Leading progress on trans fat elimination in Mexico and Pakistan [Internet]. Geneva: NCD Alliance, 2019 [cited 2020 Jun 28]. Available from: https://ncdalliance.org/news-events/news/leading-progresson- trans-fat-elimination-in-mexico-and-pakistan

  20. Rosenbaum SE, Glenton C, Wiysonge CS, Abalos E, Mignini L, Young T, et al. Evidence summaries tailored to health policy-makers in low- and middle-income countries. Bull World Health Organ. 2011;89:54-61. https:// doi.org/10.2471/BLT.10.075481

  21. Dobrow MJ, Goel V, Upshur REG. Evidence-based health policy: Context and utilisation. Soc Sci Med. 2004;58(1):207-17.

  22. Hanney SR, Gonzalez-Block MA, Buxton MJ, Kogan M. The utilisation of health research in policy-making: concepts, examples and methods of assessment. Heal Res Policy Syst. 2003;1(1):2. https://doi.org/10.1186/1478-4505-1-2

  23. Innvær S, Vist G, Trommald M, Oxman A. Health policy-makers’ perceptions of their use of evidence: A systematic review. J Health Serv Res Policy. 2002;7(4):239-44.

  24. Weiss CH. The many meanings of research utilization. Public Adm Rev. 1979;39(5):426.

  25. Davis P, Howden-Chapman P. Translating research findings into health policy. Soc Sci Med. 1996;43(5):865-72. https://doi.org/10.1016/0277- 9536(96)00130-x

  26. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ. 1997;157(4):408-16.

  27. Pope C. Contemporary social movement resisting evidence: the study of evidence-based medicine as a contemporary social movement. 2003;7(3): 267-82. https://doi.org/10.1177/1363459303007003002

  28. Canadian Health Services Research Foundation. Issues in linkage and exchange between researchers and decision makers. Ottawa, ON, Canada: Canadian Health Services Research Foundation, 1999 [cited 2020 Jan 5]. Available from: https://www.cwhn.ca/en/node/24048

  29. Crewe E, Young J. Bridging research and policy: context, evidence and links. London: Overseas Development Institute, 2002.

  30. Lomas J. Using “linkage and exchange” to move research into policy at a Canadian foundation. Health Aff. 2000;19(3):236-40.

  31. World Health Organization. Meeting on health systems strengthening and primary health care. Manila: WHO, 2008.

  32. Travis P, Bennett S, Haines PA, Pang T, Bhutta PZ, Hyder AA, et al. Overcoming health-systems constraints to achieve the Millennium Development Goals. Lancet. 2004;364(9437):900-6.

  33. Lavis JN, Posada FB, Haines PA, Osei E. Use of research to inform public policymaking. Lancet. 2004;364(9445):1615-21.

  34. Moat KA, Lavis JN. 10 best resources for evidence-informed health policy making. Health Policy Plan. 2013;28(2):215-8. https://doi. org/10.1016/S0140-6736(04)17317-0

  35. Lomas J, Shi M, Anderson GM, Hannah WJ, Vayda E, Singer J. Opinion leaders vs audit and feedback to implement practice guidelines: delivery after previous cesarean section. JAMA. 1991;265(17):2202-7.

  36. Oxman AD, Vandvik PO, Lavis JN, Fretheim A, Lewin S. SUPPORT Tools for evidence-informed health Policymaking (STP) 2: Improving how your organisation support the use of research evidence to inform policymaking. Chinese J Evidence-Based Med. 2010;10(3):247-54.

  37. Campbell DM, Redman S, Jorm L, Cooke M, Zwi AB, Rychetnik L. Increasing the use of evidence in health policy: Practice and views of policy makers and researchers. Aust New Zealand Health Policy. 2009;6(1).

  38. Dobrow MJ, Goel V, Upshur REG. Evidence-based health policy: context and utilisation. Soc Sci Med. 2004;58:207-17.

  39. Bowen S, Zwi AB. Pathways to “Evidence-Informed” Policy and practice: A framework for action. PLoS Med. 2005;2(7):e166. https://doi. org/10.1371/journal.pmed.0020166

  40. Onwujekwe O, Mirzoev T, Russo G, Etiaba E, Mbachu C, Mirzoev T, Uzochukwu B. Role and use of evidence in policymaking:an analysis of case studies from the health sector in Nigeria. Health Res Policy Syst. 2015;13:46. https://doi.org/10.1186/s12961-015-0049-0

  41. Rychetnik L, Hawe P, Waters E, Barratt A, Frommer M. A glossary for evidence based public health. J Epidemiol Community Health. 2004;58:538-45.

  42. World Health Organization. WHO plan to eliminate industrially-produced trans-fatty acids from global food supply [Internet]. Geneva: WHO, 2018 [cited 2020 Jun 28]. Available from: https://www.who.int/news-room/ detail/14-05-2018-who-plan-to-eliminate-industrially-produced-trans-fattyacids- from-global-food-supply

  43. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63(suppl 2):S5-21. https://doi.org/10.1038/sj.ejcn.1602973




2020     |     www.medigraphic.com